Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer
NCT ID: NCT05444270
Last Updated: 2023-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
270 participants
INTERVENTIONAL
2022-10-26
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the 1980\~1990s, whole abdomen irradiation had been tried and faded out owing to many side effects with the introduction of taxane. Efforts have been made to find the role of salvage radiation therapy (RT) in recurrent ovarian cancer. Involved field radiotherapy (IFRT) emerged to cover the gross tumor plus regional microscopic disease in addition to salvage chemotherapy. It showed high local control, provided chemotherapy holiday in selected cases, but did not prevent out-field progression. Stereotactic ABlative Radiotherapy (SABR) is the latest treatment using an intensity modulated technique to increase the fractional dose, reduces the number of treatments, and destroys the tumor with high accuracy. SABR-COMET study, a representative clinical study, showed a significant increase in overall survival in solid cancers.
Objectives The primary objective; to evaluate whether the addition of SABR to standard salvage treatment significantly improves 3-year overall survival (OS) in patients with recurrent ovarian cancer.
The secondary objectives;
* to check whether it significantly affects quality of life (Health-related QoL), patient-reported outcome (PRO)
* to develop an deep learning-based predictive model for the treatment response of ovarian cancer subjects using radiomic and genomic analysis.
Study design Arm 1; Standard salvage therapy Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
Arm 2; Standard salvage therapy+ SABR Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
Stratification factors
1. The number of No ascites, Platinum-sensitive, Normal CA125 and ECOG０-１; 0\~3 vs. 4
2. Location of the lesion; Lymph node lesion vs. Non-lymph node lesion
3. PARP inhibitor; Used vs. Not used
Randomization Arm 1 : Arm 2 = 1 : 2
Estimated Accrual :
* The sample size 270 was calculated by setting the sample size to a Type I error rate (α) of 0.05 and Statistical Power of 80% using 2-Sided Equity and log-rank test.
* Accurate time: 2 years, Follow-up: 3 years (total 5 years)
* Alpha = 0.05, Power = 80%
* 1 year drop-out: 5% per group
* 3 year survival proportion: RT group 74.42%, No RT group 58%
* Arm 1: Arm 2 = 1 : 2 ratio
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1 20 Gy 16-24 Gy 3 30 Gy 24-33 Gy 5 35 Gy 25-40 Gy 10 40 Gy 35-45 Gy
Patient Evaluation:
* Interviews
* It was performed 3, 6, 9, 12, 18, 24, 30, and 36 months after the end of treatment.
* Medical history listening, physical examination and assessment of all possible side effects
* The relevant examination can be prescribed if necessary.
* Imaging examination
* one of CT or PET-CT including areas suspected of recurrence or treatment is possible.
* If PET-CT was not performed within two months before treatment, it is recommended to perform PET-CT before treatment NOTE: Before treatment, it is recommended to perform the same examination as the imaging test that evaluated the treatment site.
* Tumor marker CA125 examination: performed on every visit after radiation therapy.
* Survey EORTC-QLQ-C30 questionnaire; prior to radiation therapy, 12, 24, and 36 months after treatment FACIT-TS-G (Arm 2 subjects); before radiation therapy, 12, 24, and 36 months after treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard salvage therapy
Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
Standard salvage therapy
Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
Standard salvage therapy + SABR
Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
Standard salvage therapy + SABR
Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard salvage therapy
Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
Standard salvage therapy + SABR
Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Should have completed standard treatment for the primary tumor initially. (In the case of advanced ovarian cancer, maximal debulking operation and adjuvant platinum-based chemotherapy are performed according to the stage)
* Number of metastases allowed: ≤ 10 (Adjacent lesions can be counted as a single lesion if possible to be included in a single radiotherapy treatment plan) (left cervical lymph node, right cervical lymph node, center of the left lung, periphery of the left lung, left pleura, center of the right lung, periphery of the right lung, right pleura, mediastinal lymph node, left lobe of the liver, right lobe of the liver, perihepatic space, spleen, perisplenic space, within 2 vertebrae above or below based on the spine with the lesion, abdominal cavity, pelvic cavity, paraaortic lymph node, and pelvic lymph nodes)
* Maximum diameter of each metastasis site of gross tumor ≤ 5 cm
* Age ≥ 19 year old
* Sufficient bone marrow function on tests performed within 60 days prior to study enrollment, including:
* Absolute neutrophil count (ANC) ≥ 500 / mm3
* Platelet ≥ 50,000 / mm3
* Hb ≥ 8.0 g / dl (Treatments such as blood transfusions to maintain hemoglobin count are permitted)
* Zubrod daily living performance ≤ 2 within 60 days prior to study enrollment
* Subjects must submit research-related informed consent prior to participation in the study
Exclusion Criteria
* Diffuse peritoneal carcinomatosis
* Exudative, hematological, or cytologically proven malignant exudate (Malignant pleural effusion)
* If previously treated with radiation therapy to metastases
* When targeting is difficult because the boundary of the metastasis site is not clear
* Coexisting or previous invasive cancer (excluding Thyroid cancer, Cervix CIS, basal cell carcinoma of skin, early gastric cancer) has not been disease-free for more than 3 years.
* Pregnancy
* Serious comorbidities defined as below
* Unstable angina or congestive heart failure requiring hospitalization within the last 6 months
* Deep myocardial infarction within the last 6 months
* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment
* At the time of enrollment, exacerbation of chronic obstructive pulmonary disease or other respiratory disease that requires hospitalization or makes it difficult to proceed with treatment in this study.
19 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yonsei University Health System, Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Park S, Kim H, Wee CW, Kim YS, Choi JH, Kim YS, Lee JH, Choi Y, Kim JH, Cho Y, Kim HJ, Park YJ, Park W, Eom KY, Kim YH, Kim YB. Radiotherapy quality assurance program of ongoing clinical trial using stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a dummy run study of a prospective, randomized, multicenter phase III trial (KGOG 3064/KROG 2204). BMC Cancer. 2025 Aug 18;25(1):1336. doi: 10.1186/s12885-025-13892-9.
Kim YB, Byun HK, Wee CW, Kim H, Kim S, Yang G, Kim J, Park SJ, Lee JY. Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC). BMC Cancer. 2023 Oct 20;23(1):1014. doi: 10.1186/s12885-023-11407-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4-2022-0286
Identifier Type: -
Identifier Source: org_study_id